RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Follow-Up Questions
Redhill Biopharma Ltd 的 CEO 是誰？
Mr. Dror Ben-Asher 是 Redhill Biopharma Ltd 的 Chairman of the Board，自 2009 加入公司。
RDHL 股票的價格表現如何？
RDHL 的當前價格為 $1.7，在上個交易日 decreased 了 0%。
Redhill Biopharma Ltd 的主要業務主題或行業是什麼？
Redhill Biopharma Ltd 屬於 Pharmaceuticals 行業，該板塊是 Health Care
